MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis

Inclusion Criteria: * male or female children (age ≥ 8 y.o) and adult patient with a diagnosis of cystic fibrosis provided by genetic and swear test older than 8 years. Subgroups of patients will be defined according to: * age: younger or older 18y.o. We expect around 50% in different subgroups. In case of, we reach 50% in one of these groups, patient recruitment will continue for both groups until the expected number of patients in the study is reached. * brand name of magnet: Siemens, General Electric or Philips * new drugs use: association Ivacaftor/lumicaftor (OrkambiØ) or Ivacaftor only (Kalydeco Ø) ) We expect approximately 20% to 50% of patients treated * Informed consent provided to the patient or/and to legal representative for adults and to parents for the children * Patient concerned by articles L 1121-6, L 1121-7, and L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent) if the expected benefit for such persons justifies the foreseeable risk incurred Exclusion Criteria: * patients without any social security or health insurance * pregnant women * Patients with previous pulmonary transplantation or planned for transplantation in the year following inclusion * MRI contraindications: